Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 31;7:132. doi: 10.1038/s41541-022-00537-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — The panels show the difference in the production of 27 cytokines (using combined DENV capsid/pre-membrane and envelope region peptide pools) at day 56 (a) and the concentrations of cytokines showing a greater than two-fold change in at least four vaccinated individuals (b) (adapted according-to-protocol cohort for immunogenicity subset). Error bars represent the Min and Max values in each group. CME, combined capsid/pre-membrane and envelope; D, day; D56, 28 days post-dose 2; DENV, dengue virus; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IP-10, interferon-inducible protein 10; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; NC, negative control; PDGF, platelet-derived growth factor; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. *Significant difference in the DPIV groups comparing NC vs CME stimulation as assessed by Holm-Sidak using α = 0.05; computations assumed that all time points were sampled from populations with the same scatter.